Stallergenes Greer: Alustal®, the Company’s Subcutaneous Allergen Immunotherapy Treatment (SCIT) Now Available
Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces that Alustal®, its subcutaneous allergen immunotherapy (SCIT) solution, is now available in Italy and Spain following the full resumption of SCIT production in Antony (France). Alustal® will be also available in Australia, France and Switzerland in the coming months.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005500/en/
“We are pleased that patients and the medical community have access to an alternative allergen immunotherapy option with Alustal®. Stallergenes Greer’s comprehensive SCIT offering is the result of sustained investments in state-of-the-art manufacturing facilities and quality systems and reflects our commitment to offer a wide range of personalised treatment options which meet physicians’ needs for precision treatment” declares Amer Jaber, Executive VP Operations Europe & International.
Stallergenes Greer’s SCIT products meet the needs of patients whose profile and lifestyle require an alternative access to treatment and delivery mode, longer intervals between treatment, or monitoring of adherence by their physician. The company’s SCIT offering also includes Albey® which will be progressively reintroduced and Alyostal® prick tests.
Stallergenes Greer is committed to developing a wide portfolio of precise personalised treatment solutions tailored to each patient profile and to each market, including diagnostics, injectable therapies and sublingual therapies such as drops and tablets.
ABOUT ALUSTAL®
Alustal® is an aluminium-based suspension for subcutaneous injection launched in 1997.The aluminum adjuvant allows the slow release of antigen at the injection site to stimulate the immune response.
Alustal® is indicated for Type I allergies (Gell and Coombs classification) mainly involving rhinitis, conjunctivitis, rhinoconjunctivitis or asthma (mild to moderate), of a seasonal or perennial nature, in children, adolescents and adults.
ABOUT STALLERGENES GREER Ltd
Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).
Additional information is available at https://www.stallergenesgreer.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005500/en/
Contact information
Communications
Catherine Kress
Tel: +33 (0)1 55 50 26 05
Email: catherine.kress@stallergenesgreer.com
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dataocean AI Unveils NEW Brand, NEW Site, and NEW Multilingual Speech Corpus for Speech Foundation Models at ICASSP 202416.4.2024 07:00:00 CEST | Press release
Dataocean AI, a global data services provider, is pleased to announce a NEW brand, a NEW site, and a NEW Multilingual Speech Corpus for Speech Foundation Models at ICASSP 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415891226/en/ Dataocean AI's New Website (Graphic: Business Wire) Dataocean AI announced the upgrade of its branding at ICASSP. The new brand, characterized by dynamic gradient design, symbolizes the company's unwavering commitment to excellence and innovation in the AI data industry. With almost 20 years of experience in the AI data industry, Dataocean AI will continue to innovate, subvert the industry with technology, and provide cost-effective data products and services for over 900 enterprises and research institutes globally. Meanwhile, Dataocean AI launched the new site. A key highlight of the new site is that they have created an e-commerce model for shopping datasets, making it more accessible
GridBeyond Closes €52M Series C Funding Round to Continue Its Platform Evolution and Invest in New & Existing Markets16.4.2024 06:00:00 CEST | Press release
GridBeyond, the leading intelligent energy and smart grid platform provider for distributed energy resource management, has closed its €52M Series C financing round. The round was led by Alantra’s Energy Transition Fund, Klima. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415760197/en/ GridBeyond closes €52M Series C funding round to continue its platform evolution and invest in new & existing markets. (Graphic: Business Wire) The Series C round also included new investors Energy Impact Partners, Mirova, ABB, Constellation and Yokogawa Electric Corporation as well as investment from existing investor, Act Venture Capital. Since its foundation in 2010, GridBeyond has been developing its AI platform to help businesses unlock the full potential of energy assets, ensuring the sustainability, resilience, and affordability of energy as the world moves towards a zero-carbon future. GridBeyond’s technology unleashes the latent
Westinghouse Congratulates Energoatom on Start of AP1000 ® Work at Khmelnytskyi NPP15.4.2024 23:17:00 CEST | Press release
Westinghouse Electric Company congratulates Energoatom, the state-owned nuclear utility of Ukraine, on the start of AP1000® activities at Khmelnytskyi Unit 5 in Ukraine. This is a critical first step in advancing the commitment made by both companies under the Memorandum of Understanding signed in 2022 for the deployment of nine AP1000 reactors in Ukraine. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415282247/en/ Westinghouse Electric Company congratulates Energoatom on the start of AP1000® activities at Khmelnytskyi Unit 5 in Ukraine. (Photo: Business Wire) Today’s news follows the arrival of the first batch of Westinghouse VVER-1000 nuclear fuel for the two operating units at the Khmelnytskyi Nuclear Power Plant in March 2024. The VVER-1000 fuel was manufactured at Westinghouse’s fuel fabrication facility in Sweden, which also delivered the first batch of VVER-440 nuclear fuel to Ukraine’s Rivne Nuclear Power Plant i
World Famous Soccer Star Neymar Junior Joins Forces With Fun Brands and Enters the Cocktails and Mocktails Business With His Own Brand15.4.2024 18:00:00 CEST | Press release
Neymar da Silva Santos Júnior, known as one of the best soccer players in the world, joins forces with Fun Brands, a Miami, Florida-based beverage company, to announce a new collaborative venture of innovative, all-natural spirit- and wine-based cocktails and zero alcohol mocktails launching in Brazil later this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415201897/en/ World Famous Soccer Star Neymar Junior Announces Collaborative Venture With Fun Brands to Enter Cocktail and Mocktail Business With Own Brand (Photo: Business Wire) “This is a great opportunity for me to celebrate in a new way with my fans worldwide, creating possibilities for connection beyond soccer, which is my life,” highlighted the All-star. “I want to share the flavors of Brazil that I love the most with my soccer fans at home and around the world in a different and irreverent way. The idea of also offering non-alcoholic beverages greatly att
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome15.4.2024 15:15:00 CEST | Press release
On Friday, 12th April, 2024, Professor Julia Scarisbrick of University of Birmingham presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSA: 4151)-sponsored study, “Real-World Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER)”, a prospective observational study evaluating the real-world impact of mogamulizumab on disease symptoms and health-related quality of life (HRQoL) in patients with these subtypes of cutaneous T-cell lymphoma (CTCL). CTCL is a rare form of non-Hodgkin lymphoma that most prominently affects the skin, presenting as patches, plaques, tumours, or reddening of the entire skin, and may be associated with severe itching. In a proportion of cases, the disease may spread to the lymph nodes, blood, and/or other organs. In the current interim analysis, symptom scores (mean) were reported for 20 adult patients with relapsed or refractory disease (8 MF; 12 SS) over their first 16 weeks of mogamulizumab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom